Azelis acquires Azienda Chimica e Farmaceutica to expand presence in Italy
Azelis will strengthen its presence in the domestic market by leveraging portfolio synergies, actively consolidating the business, and creating value for all stakeholders
Azelis will strengthen its presence in the domestic market by leveraging portfolio synergies, actively consolidating the business, and creating value for all stakeholders
Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases
Acquisition to be followed by merger; strengthens Torrent’s IPM market presence
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio
Ideal for extreme dry skin and hyperkeratotic conditions such as psoriasis and ichthyosis, Ureaderm offers the next step in evidence-based, effective skin hydration
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
This significant milestone enhances our global regulatory standing
The transaction structured as share swap, is valued at ~Rs. 849 crore, with no cash outflow
Subscribe To Our Newsletter & Stay Updated